Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.58 USD
+1.90 (0.81%)
Updated May 6, 2024 04:00 PM ET
After-Market: $236.60 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.58 USD
+1.90 (0.81%)
Updated May 6, 2024 04:00 PM ET
After-Market: $236.60 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BDX vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
by Zacks Equity Research
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BD's (BDX) ADC System Favored by New Study for Long-Term Care
by Zacks Equity Research
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
Here's Why You Should Retain BD (BDX) to Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease
by Zacks Equity Research
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
by Zacks Equity Research
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BDX or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Philip Morris, General Dynamics, Becton, Dickinson, Cheniere Energy and Aflac
by Zacks Equity Research
Thermo Fisher Scientific, Philip Morris, General Dynamics, Becton, Dickinson, Cheniere Energy and Aflac are included in this Analyst Blog.
Earnings Season Scorecard and Analyst Reports for Thermo Fisher, Philip Morris & General Dynamics
by Sheraz Mian
Today's Research Daily features the real-time earnings season scorecard and updated analyst reports on Thermo Fisher (TMO), Philip Morris International (PM) and General Dynamics (GD).
Three Reasons to Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.
Becton Dickinson (BDX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Becton Dickinson (BDX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 12.13% and 0.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of -4.51% and 1.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test
by Zacks Equity Research
BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.
Becton Dickinson (BDX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
BD (BDX) Collaborates With Hamilton to Benefit Researchers
by Zacks Equity Research
Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.